Showing 631-640 of 9078 results for "".
Robert Grant Steps Down at Alphaeon; Skin Cancer Special Edition
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-robert-grant-steps-down-at-alphaeon-skin-cancer-special-edition/18595/Robert Grant is no longer CEO of lifestyle healthcare company Alphaeon. Mr. Grant founded Alphaeon in 2013 as a wholly owned subsidiary of Strathspey Crown LLC, a private equity firm located in Newport Beach, CA, where he serves as Chairman. Also in this issue, a closer look at skin cancer. May is SDrug Prices Soar, Amgen Files BLA for Biosimilar to Humira
https://practicaldermatology.com/topics/practice-management/dermwiretv-drug-prices-soar-amgen-files-bla-for-biosimilar-to-humira/18672/In this edition, Amgen Submits ABP 501—first Adalimumab biosimilar; prices for dermatology drugs jump and a survey explores patient knowledge of antibiotic resistance. Also, Almirall acquires Veltin from Sitefel/GSK.Aesthetic Combinations: Recent Advancements
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/aesthetic-combinations-recent-advancements/18882/Greg Buford, MD discusses advancements in aesthetic practice, including the most popular interventions among patients and his favorite approaches to patient management.Onexton Approved for Acne, Bellafill Debuts
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-onexton-approved-for-acne-bellafill-debuts/19019/In this edition of DermWireTV, from the editors of Practical Dermatology® magazine: Onexton is Valeant's fourth new approval in a year. We look at Suneva's renamed filler and the FDA's decision to grant breakthrough status to investigational atopic dermatitis treatment dupilumab. PLUS: This week'sDASIL and the ASDS
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dasil-and-the-asds/19054/A new partnership between DASIL and the ASDS is intended to improve and expand education for dermatologists and cosmetic surgeons. Michael H. Gold, MD explains.Merz Acquires Ulthera; Ulthera Gets Decolletage Indication, and a New Topical for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-merz-acquires-ulthera-ulthera-gets-decolletage-indication-and-a-new-topical-for-onychomycosis/19117/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine, learn the latest on the Merz/Ulthera acquisition, a new topical for toenail fungus, and FDA accepts Kythera's NDA.Skin Resurfacing, Pixel RF from Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/-skin-resurfacing-pixel-rf-from-alma-lasers/19241/Skin resurfacing with the innovative Pixel RF from Alma Lasers. Ready to fight the hands of time? Click here for more info: http://www.AlmaLasers.comVShape Facial Contouring by Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vshape-facial-contouring-by-alma-lasers/19251/VShape is a non-invasive and pain-free treatment for facial contouring. Performed throughout the world using Alma Lasers Accent Ultra medical aesthetic technology. vShape: Bipolar RF TechnologyPsoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.